Whether TNF inhibitors prevent structural damage in ankylosing spondylitis remains a controversial topic, as three prospective trials failed to show any evidence to support this notion. However, data are accumulating from retrospective analyses of well-characterized cohorts of patients that could provide the solution to this controversy.
Refers to Molnar C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis.http://dx.doi.org/10.1136/annrheumdis-2017-211544 (2017)